“Cell BioEngines, Inc., is a clinical-stage biotech company focused on developing allogeneic ‘off-the-shelf’ stem cell and its derived therapies as ‘drugs’ for human disease treatment. Its lead product is currently in Phase 1 trials for the treatment of hematopoetiic neoplasms not curable with available therapies, particularly acute leukemia and myelodysplasia. It also has three pre-clinical cell-based assets in development for oncology patients and regenerative medicine applications.  

The company’s proprietary platform technology is what makes it innovative and unique. It’s “”Cell BioEngineMAP”” is a cutting-edge platform for developing cell therapy assets, leveraging the remarkable potential of universal umbilical cord-derived blood stem cells. These cells serve as a foundational source, which we expand, differentiate, and de-differentiate to produce powerful cells at large scale for clinical applications. Complementing this, our “”Cell BioEngineAI”” platform employs artificial intelligence to predict donor availability and target characteristics, ensuring the safety and efficacy of HLA-compatible therapies. Our goal is to create a ready-to-use, ‘off-the-shelf’ cell bank with therapeutic products that cover over 85% of the population, available at selected blood centers.”